FDA Says Onglyza Label Should Include Heart Failure Risk, Reports Lawsuitsettlementnews.com
Lawsuit Help Center website reports Type 2 diabetes medication, Onglyza, sold by AstraZeneca, is linked to a possible rise in heart failure risks, although the FDA spares the company from removing it from the market.
JERSEY CITY, N.J., June 11, 2015 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, announced today that the Type 2 diabetes medication, Onglyza, is linked to an increase in possible heart failure, in which the FDA panel has requested a warning on its label. Onglyza has already been the target of potential side effects of lawsuits involving risks of pancreatitis as well as possible cancer. Onglyza was designed to help people with Type 2 diabetes (who do not suffer from diabetic ketoacidosis) by helping controlling high blood sugar. Onglyza effectively controls blood sugar, and unlike other diabetes medications, the drug does not encourage weight gain. Despite the positive effects of Onglyza, some doctors are concerned over reports of the possibility of increased risk of pancreatitis and cancer (pancreatic and thyroid cancer). Currently, there are hundreds of filed lawsuits from people who have developed pancreatitis or pancreatic cancer, alleging that the company failed to warn patients of the risks associated with the drug. There has also been a SAVOR study involving about 16K patients, with results that show that there was a 27% difference in heart failure hospitalizations between the Onglyza group and the control group. The FDA panel voted in favor of adding the information about the risk of heart failure to the label, however, they are not pulling it from the market at this time. Experts now expect patients who have been hospitalized, or family members who have died of heart failure, will begin to pursue lawsuits against Onglyza's manufacturer, AstraZeneca, now that the FDA label has been mandated.
Chris Janish, CEO of MTS, commented on the recent reports and concerns over Onglyza, "It is disappointing that the new data shows a serious side effect in patients taking Onglyza and possible heart failure. We have seen this before with other blockbuster drugs, and we remain here to assist patients, or their family members, who have been linked to heart issues at the taking of Onglyza. The lawyers in our network are at the forefront of the Onglyza litigation, and can provide patients and their families with a free case evaluation."
MTS is ready and able to assist those who need lawsuit help with obtaining an Onglyza law firm or Onglyza lawyer to provide a free evaluation on their specific case. To learn more about MTS' services involving Onglyza and other bad drug litigations, please visit: http://www.lawsuitsettlementnews.com/onglyza-cases
If you already have an attorney and have filed a lawsuit and need a lawsuit funding cash advance or lawsuit money, not to be confused with a lawsuit loan or pre-settlement loan, Lawsuit Settlement News can assist you with these services. Injured parties from Onglyza usage and/or complications can apply for pre-settlement. For a full list of the services that the company provides, visit: http://www.lawsuitsettlementnews.com/about-our-products-and-services
If you, or a loved one, have suffered complications from Onglyza and need lawsuit help, including finding an Onglyza attorney or law firm, please call 877.571.0405.
You may also fill out a quick application online at: www.lawsuitsettlementnews.com and an agent will contact you shortly.
MT Services LLC, operator of Lawsuitsettlementnews.com, is not a law firm and cannot provide legal advice on your case; however, MTS works with lawyers involved in mass tort litigations who are willing to provide a free legal consultation at the consumer's request. For a list of full disclosures please visit the company's website disclosure page.
Contact: Chris Janish, CEO
Ph. 877.571.0405
SOURCE MT Services LLC
Share this article